Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered

R. Revilla, Revilla R, Revilla M, M. Revilla, E. R. Hernández, Hernández ER, L. F. Villa, Villa Lf, L. Varela, Varela L, Rico H, H. Rico
Maturitas · 1995 · vol. 22(2) , pp. 145–150 · doi:10.1016/0378-5122(95)00929-f · PMID:8538483 · W2154443166
article OA: closed CC0 ⤵ 14 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study demonstrates that bone mass loss induced by GnRH agonists is not fully reversible.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

There is disagreement as to whether the loss of bone mass induced by GnRH agonists is reversible. In part, the differences of opinion might be attributed to the fact that the influence of weight and seasonal changes on bone mass is often overlooked. Taking into consideration weight and seasonal changes in bone mass, total (TBBMC) and regional body bone mineral content were measured in 38 women treated with GnRH agonists for 6 months for endometriosis or leiomyomata. Measurements were made at the onset of treatment, at 6 months of treatment and at 6 months after finishing treatment. TBBMC was corrected for body weight. Body weight had increased significantly at 6 months of treatment (P = 0.0175). Regional bone mineral content showed the following: limbs, no changes; head, significantly lower at 12 months than at baseline (P = 0.0036) and at 6 months (P = 0.0343) of therapy; trunk, significantly lower at 6 months (P = 0.0002) compared to baseline, but the values at 1 year were not significantly different from either the baseline or the 6-month values; pelvis, the same pattern of change as in the trunk (P = 0.0349). TBBMC was significantly lower at 6 months of treatment (P < 0.0001) and at 1 year (P = 0.0162). TBBMC adjusted for weight experienced the same changes as unadjusted bone mineral content (P < 0.0001 and P < 0.0009 at 6 months and 1 year, respectively). Our findings indicate that the bone mass lost with GnRH treatment had not been restored 6 months after discontinuing treatment.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Bone Density Endometriosis Luteolytic Agents Triptorelin Pamoate Adult Anthropometry Bone Density Endometriosis Female Humans Luteolytic Agents Luteolytic Agents Triptorelin Pamoate Triptorelin Pamoate

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (14)

Source provenance

europepmc
last seen: 2026-08-12T06:07:16.479679+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:13.665691+00:00
unpaywall
last seen: 2026-08-12T06:43:03.944938+00:00
License: CC0 · commercial use OK